CT colonography promotion belies gold standard preference of imagers
For the last several years, radiology imaging journals have been eager to discuss colonic assessment by CT, as in your August 2006 edition ("Multinational study cements safety of CT colonography," page 14). Like many radiologists, I attend sundry meetings and, for the last two years, have queried fellow physicians as to how they wish to be evaluated in the colon.
Less than 5% of the radiologists suggested CT evaluation. If one is to be assessed by either CT or classic colonoscopy, the preparation is essentially the same. Overwhelmingly, physicians go for the gold standard.
Why don't the editors stop comforting CT manufacturers that are trying to make more money and recognize that traditional colonoscopy is the study of choice?
>-Richard Hamilton, M.D.
New York, NY
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
